National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.

Rapid Review

Commenced Completed Outcome
17/08/2011 31/08/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/11/2011 02/4/2012  Reimbursement not Recommended


The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.

Rivaroxaban for AF summary


Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012).  At this revised price we now consider rivaroxaban cost effective for this indication.  A positive recommendation was made on the 19/6/2012.